- Evotec sells its Halle-based chemical API manufacturing site to Monacum Partners as part of a strategic focus shift.
- The facility will operate as DAPIN GmbH under new ownership, with all employees retained.
Evotec SE has announced the sale of its chemical API-focused CDMO facility, Evotec DS GmbH, located in Halle/Westphalia, Germany, to private equity firm Monacum Partners. The divestment is part of Evotec’s “Priority Reset” initiative, launched in April 2024, designed to streamline the company’s focus on core business sectors and support profitable growth.
The facility, which will now operate under the name DAPIN GmbH (Deutsche API & Intermediates), specialises in chemical APIs, intermediates, and building blocks. It offers a full range of CDMO services from development through to commercial-scale manufacturing, catering to pharmaceutical clients across various markets.
Monacum Partners has committed to maintaining and growing the business, ensuring continuity for all current operations and the entire workforce. The acquisition aims to support Evotec DS’s growth aspirations, while aligning Evotec’s resources towards its core strategic initiatives.
“This transaction will allow Evotec to focus on its primary growth drivers while providing Evotec DS with the opportunity to pursue further expansion,” the company stated in its announcement. Financial terms of the deal were not disclosed.
Overview of outsourcing trends 
